Treatment of Cerebral Toxoplasmosis in Pregnancy
Clinical Scenario
Toxoplasma encephalitis (TE) occurring during pregnancy is an urgent clinical situation. Pregnancy introduces specific considerations that shape both the choice of treatment and the timing of intervention, requiring careful clinical judgment and specialist involvement.
Pregnancy Context
In pregnant patients with TE, the general treatment approach mirrors that used in other adults — but gestational age directly influences which agents are appropriate. The potential for fetal harm from certain agents must be weighed against the serious risk that untreated or undertreated encephalitis poses to the mother.
Treatment Approach (Partial Overview)
Management centres on combination antimicrobial therapy. Decisions around which regimen to use depend in part on the trimester of pregnancy — some agents raise teratogenicity concerns in early gestation, yet may still be appropriate given disease severity. Alternative regimens exist when first-choice agents are not available.
The complete regimen — including specific agent selection, trimester-specific guidance, and sequencing — is in the full protocol below.
References
- During pregnancy, treatment of TE should be the same as in other adults with HIV (BIII), including pyrimethamine plus sulfadiazine plus leucovorin (AIII), and in consultation with appropriate specialists (BIII).
- In general pyrimethamine should be avoided in the first trimester of pregnancy because of teratogenicity concerns, but in the case of TE, the benefit of using pyrimethamine to the mother outweighs the risk to the fetus.
View source ↗